The Department of Health and Human Services (HHS), through its Office of the Assistant Secretary for Preparedness and Response (ASPR), has obligated $696,665,954 to date to Phlow Corp. under contract 75A50120C00092, according to federal spending data published on USAspending.gov.

The contract description identifies the work as "US based advanced API manufacturing," with base period funding supporting U.S.-based advanced manufacturing of COVID-19 essential medicines and future threats. In this context, API refers to active pharmaceutical ingredient — the chemical compound that gives a drug its therapeutic effect — not a software application programming interface.

The award, first put in place in 2020, was designed to rebuild domestic capacity to produce essential generic medicines and their active pharmaceutical ingredients, much of which had migrated to overseas manufacturers in recent decades. The obligated amount reflects funding drawn down over the life of the contract, which has included base commitments and subsequent option exercises.

For government contractors in the pharmaceutical and health-security space, the award underscores continued federal investment in supply-chain resilience for critical medicines. Sustained obligations under contracts like this one signal ongoing agency demand for onshore manufacturing capability, an area that has drawn sustained attention from HHS and ASPR since the early stages of the COVID-19 pandemic as a hedge against reliance on foreign API sources for drugs the Food and Drug Administration considers essential.

The award is administered by ASPR, the HHS office responsible for coordinating federal public health and medical preparedness, including the Biomedical Advanced Research and Development Authority's efforts to secure domestic sources for medical countermeasures and medicines in shortage.

Source: USAspending